Hemostemix Inc. (CVE:HEM – Get Free Report) was up 38.1% on Wednesday . The company traded as high as C$0.15 and last traded at C$0.15. Approximately 605,625 shares were traded during mid-day trading, an increase of 56% from the average daily volume of 387,760 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Up 20.0 %
The company has a market capitalization of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20. The business has a fifty day simple moving average of C$0.09 and a two-hundred day simple moving average of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Upcoming IPO Stock Lockup Period, Explained
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Golden Cross Stocks: Pattern, Examples and Charts
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- The 3 Best Blue-Chip Stocks to Buy Now
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
